Prurigo Nodularis

Latest News

Abrocitinib Shows Promise for Prurigo Nodularis
Abrocitinib Shows Promise for Prurigo Nodularis

September 6th 2024

The JAK1 inhibitor provided significant relief for 2 patients with refractory PN.

Approximately 65% of Dermatologists in Japan Report Dissatisfaction With Treatment Options for Severe Prurigo Nodularis
Approximately 65% of Dermatologists in Japan Report Dissatisfaction With Treatment Options for Severe Prurigo Nodularis

September 6th 2024

Study Outlines Prurigo Nodularis and Psychiatric Comorbidities
Study Outlines Prurigo Nodularis and Psychiatric Comorbidities

September 3rd 2024

FDA Approves Nemolizumab for the Treatment of Prurigo Nodularis
FDA Approves Nemolizumab for the Treatment of Prurigo Nodularis

August 13th 2024

Baldo Scassellati Sforzolini, MD, PhD, MBA: Expanding Nemolizumab’s Access
Baldo Scassellati Sforzolini, MD, PhD, MBA: Expanding Nemolizumab’s Access

May 17th 2024

More News

Incyte and CMS Collaborate to Develop Povorcitinib in Numerous Chinese Regions

Incyte and CMS Collaborate to Develop Povorcitinib in Numerous Chinese Regions

Kaitlyn Bader, Senior Editor
April 1st 2024

Povorcitinib is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria.

Late-Breaking Data: Povorcitinib Significantly Improves Itch and Lesions in Prurigo Nodularis

Late-Breaking Data: Povorcitinib Significantly Improves Itch and Lesions in Prurigo Nodularis

Kaitlyn Bader, Senior Editor ;Shawn Kwatra, MD
March 12th 2024

Shawn Kwatra, MD, shares positive updates on phase 2 oral povorcitinib for prurigo nodularis at AAD 2024.

Late-Breaking Data: Long-Term Safety and Efficacy of Largest Prurigo Nodularis Study Ever Conducted

Late-Breaking Data: Long-Term Safety and Efficacy of Largest Prurigo Nodularis Study Ever Conducted

Kaitlyn Bader, Senior Editor ;Shawn Kwatra, MD
March 11th 2024

Shawn Kwatra, MD, presented late-breaking data at AAD 2024 on the largest prurigo nodularis and nemolizumab clinical trial, OLYMPIA.

FDA Accepts Galderma’s BLA for Nemolizumab for the Treatment of Prurigo Nodularis and Atopic Dermatitis

FDA Accepts Galderma’s BLA for Nemolizumab for the Treatment of Prurigo Nodularis and Atopic Dermatitis

Kaitlyn Bader, Senior Editor
February 14th 2024

The FDA has also granted nemolizumab Priority Review for prurigo nodularis.

Cryosim-1 Safe, Effective in Patients With Prurigo Nodularis

Cryosim-1 Safe, Effective in Patients With Prurigo Nodularis

Emma Andrus, Associate Editor
January 9th 2024

A randomized, placebo-controlled trial of the selective transient receptor potential melastatin 8 agonist explored its efficacy and safety in PN.

© 2024 MJH Life Sciences

All rights reserved.